SMITHS-DETECTION
10.10.2019 08:02:08 CEST | Business Wire | Press release
Global threat detection and security technologies company, Smiths Detection is showcasing for the first time an integrated checkpoint solution at inter airport Europe 2019, which harnesses biometric technology to enable risk-based screening practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005541/en/
With air passenger growth predicted to double by 2037, the aviation industry will be challenged to support this capacity growth whilst providing operational efficiencies and meeting shifting passenger expectations of the airport experience.1 To cope with this growth, biometric technology is being increasingly adopted at airport Border Control gates, bag drop and boarding gates.
As leaders in providing checkpoint solutions to airports across the world, Smiths Detection has partnered with experts in the field of biometry to, for the first time, create a proof of concept which integrates biometric identity management solutions with class-leading screening solutions. Inter airport delegates are invited to experience the biometric capable checkpoint in action – which also employs Smiths Detection’s advanced CT scanner, HI-SCAN 6040 CTiX , the iCMORE Weapons automatic object recognition capability and the advanced tray return system, iLane.evo .
Biometrics is the ‘unique identifier’ for passengers, and through integration of biometrics directly into the checkpoint, passengers can be matched with their trays to enable real-time risk-based screening. Risk-based screening is designed to increase operational efficiency and effectiveness through continual risk assessments relevant to the individual passenger journey, resulting in shorter and easier journeys for passengers.
Through passenger and tray identification, new data insights can be gathered to inform decision making at airports - based on flights, airlines or destinations. Matching passengers with trays also enables the sharing of screening results with transit or arrival airports, and the combination of hold baggage and checkpoint screening results.
“At Smiths Detection, we’re dedicated to delivering a seamless passenger journey and we are very excited to be driving biometric checkpoint technology forward in a rapidly developing marketplace,” said Smiths Detection Vice President Europe, Africa and Marketing Tony Tielen . “As a trusted partner to airports across the world, we are working with the aviation industry to deliver risk-based screening at departure, transit and arrival airports to streamline the checkpoint journey to make it even safer and more efficient.”
“Biometrics is an urgently needed solution to provide seamless checkpoint security,” said Global Market Director Aviation, Richard Thompson . “Ever increasing air passenger traffic plus advances in biometrics, artificial intelligence and integrated screening technology mean that risk-based screening is now firmly on the fast track. We look forward to offering a preview of the checkpoint solution of the future to delegates at inter airport Europe 2019.”
Enquiries:
If you would like to speak with someone regarding this press release and/or preview this checkpoint solution, Smiths Detection will be presenting at Stand 410, Hall B6 at inter airport Europe.
References and data points:
- At the beginning of 2018, SITA, the airlines technology supplier, reported that 77% of airports and 71% of airlines were planning major programs or R&D in biometric ID management over the next five years.
- Airlines are responding to demands from passengers as 57% of passengers would "definitely use biometrics" if it helps them get quicker through the boarding process, according to SITA.
- According to the IATA 2018 Passenger Survey , 45% of air travellers choose biometric identification as a replacement of their passport.
- Over 65 percent of passenger’s were inclined towards sharing additional personal information to speed up their processing at the airport. Speed and convenience are paramount, according to IATA .
Recent press releases:
- Smiths Detection launches new security scanner specifically developed for air cargo screening
- Smiths Detection secures $96.8m contract to provide checkpoint CT systems to Transportation Security Administration (TSA)
- Smiths Detection’s Largest Ever Order for HBS Systems Confirmed by Spanish Airport Operator, Aena
###
About Smiths Detection
Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.
For more information visit http://www.smithsdetection.com .
About inter airport Europe
From 8 – 11 October 2019, inter airport Europe 2019, the 22nd International Exhibition for Airport Equipment, Technology, Design and Services will take place at the Munich Trade Fair Centre in Germany.
For manufacturers and suppliers of airport equipment, technology, design and services, inter airport Europe provides the opportunity to meet specialists from airports, airlines, air cargo carriers as well as aviation support from all over the world looking to invest in future-oriented, modern solutions for the interconnected airport. The world’s leading airport exhibition is renowned for covering the most comprehensive range of products and services for the entire airport: technology and services for ground handling, airport equipment, terminal operations, airport IT solutions and airport design.
For more information visit https://www.interairporteurope.com/welcome#/
1 https://www.iata.org/pressroom/pr/Pages/2018-10-24-02.aspx
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005541/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
